Program News

Influenza Vaccination Update Letter

CDC Update: Seasonal Influenza Vaccination

Dear Healthcare Executive,

The Centers for Disease Control and Prevention (CDC) has updated its recommendations for seasonal influenza vaccination to include quadrivalent influenza vaccines1

Today’s trivalent flu vaccines help protect against two A strains, and one B strain. Flu vaccine efficacy is partly dependent on how closely related the viruses in the vaccines are to the flu viruses circulating that year. When the viruses in the vaccine are significantly different from those circulating in the community, it is called a mismatch.2 Indeed, between 2001 and 2012, the B lineage in the influenza vaccine did not match the predominantly circulating B lineage in 6 of the 11 flu seasons.3,4

Adding another B strain to the influenza vaccine to include two A strains and two B strains is a public health measure that may help close the gaps in influenza coverage.

Click to download a letter that may be forwarded to your in-network healthcare providers to inform them about the new CDC influenza vaccination recommendation for children and adults, as well as important information about seasonal influenza virus.

  • The previous information was general information about influenza disease
  • The information that follows is specific to FLUARIX® QUADRIVALENT (Influenza Virus Vaccine)
  • Approval of FLUARIX QUADRIVALENT for use in preventing influenza disease caused by influenza A and influenza B was based on immune response data
  • FLUARIX QUADRIVALENT has not been proven to have a positive impact on the potential consequences or outcomes of influenza A or influenza B
  • To determine whether FLUARIX QUADRIVALENT is right for your patients, please see the accompanying complete Prescribing Information

Indication

FLUARIX QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUARIX QUADRIVALENT is approved for use in persons 3 years of age and older.

Important Safety Information for FLUARIX QUADRIVALENT

  • Do not administer FLUARIX QUADRIVALENT to anyone with known severe allergic reactions (anaphylaxis) to any component of the vaccine, including egg protein, or a life-threatening reaction to previous administration of any influenza vaccine
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give FLUARIX QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • The tip caps of the prefilled syringes may contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals
  • If FLUARIX QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
  • Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • In clinical trials with FLUARIX QUADRIVALENT, the most common adverse reactions in adults were pain at the injection site, muscle aches, headaches, and fatigue. In children 3 through 17 years of age, injection site adverse reactions were pain, redness, and swelling. In children 3 through 5 years of age, the most common systemic adverse events were drowsiness, irritability, and loss of appetite. In children 6 through 17 years of age, the most common systemic adverse events were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLUARIX QUADRIVALENT for other potential adverse reactions and events)
  • Vaccination with FLUARIX QUADRIVALENT may not result in protection in all vaccine recipients

Click to download the CPT® code to use for FLUARIX QUADRIVALENT intramuscular injection. This one-page document may be forwarded to healthcare providers and used for updating your own records to ensure the code is correctly activated in your plan’s coding and reimbursement system.

ATTENTION: PRAN Bran Turmeric Powder is Recalled Due to Elevated Levels of Lead

Patients, family members, and friends issued supplements containing Turmeric must cease consumption immediately. Please contact your local healthcare provider to test the lead levels of your blood.

Refer to the FDA website for the full story.
Best Value, Inc., Recalls PRAN Bran Turmeric Powder Due to Elevated Levels of Lead

OxyElite Pro Dietary Supplements by USP Labs: Recall – Products Linked to Liver Illnesses

AUDIENCE: Consumers, Healthcare Professionals

ISSUE: The U.S. Food and Drug Administration announced today that USPlabs LLC, of Dallas, Texas, is recalling certain OxyElite Pro dietary supplement products that the company markets. The company took this action after receiving a letter from the FDA stating that the products have been linked to liver illnesses and that there is a reasonable probability that the products are adulterated. 
In a review of 46 medical records submitted to the FDA by the Hawaii Department of Health, the records indicated that 27 patients, or 58 percent, had taken a dietary supplement labeled as OxyElite Pro prior to becoming ill. Seventeen of the 27 patients (or 63 percent) reported that OxyElite Pro was the only dietary supplement they were taking. One death has occurred among these patients, another patient has required a liver transplant, and others await liver transplants. For a list of products affected please see the FDA News Release.
For more information visit DG Alerts